FCF Fox Corporate Finance | FCF Life Sciences Life Sciences Venture Capital Monitor – Europe February 2021 Antibody Agenda FCF LIFE SCIENCES OVERVIEW FCF Life Sciences Overview Overview Services Facts and Figures Focus on Biotech, MedTech and HealthTech Collaboration Over Over Life Sciences with Management Team of 100 years EUR 2bn We advise innovative companies on arranging, structuring and placing equity BioScience Presentation 10 in aggregated Life Sciences and debt transactions in a holistic financing approach. Valuation and Life Sciences transaction based in Munich Integrated YAFO Capital experience volume1 Financial Modeling Focus Areas Over Post- Access to 7 Transaction 80 Leading > 1500 regularly FCF advises with its dedicated Life Sciences team on the following Support completed Life published Life international EIB advisor transaction types: Sciences Sciences Investor investors in Europe Screening transactions1 reports 1 including Professionals and Life Sciences Advisors Investor / IB Venture China Roadshow Equity Life Sciences Research Series Debt Licensing Due Diligence Support Life Sciences Venture Biotech Venture Capital Monitor – US Equity & Debt Capital Monitor – Europe Life Sciences Team Fundraising Financing Strategy Advisory Life Sciences Venture Biotech Licensing Capital Report Monitor – China Closing Assistance Prof. Dr. Arno Fuchs Dr. Alexandra Dr. Joachim Alexander Kuhn Horst Domdey CEO Goll M. Greuel Analyst Life Sciences Life Sciences Life Sciences Term Sheet Advisor Advisor Advisor Negotiation Biotech Public Equity MedTech Public Equity IPO Monitor Monitor Execution Support Life Science Advisory Life Sciences IPO Dr. Axel Polack Claus Schalper Dr. Mathias Enno Spillner Sebastian (extract from service Board Report Life Sciences Life Sciences Schott Life Sciences Sommer portfolio) Advisor Advisor Director Advisor Associate 3 Executive Summary The FCF Life FCF Life Sciences Venture Capital Monitor - Europe Recipients Sciences Venture Capital Monitor - is a monthly published overview of Biotech, Pharmaceutical, The FCF Life Sciences Venture Capital Monitor - Europe targets the Europe is a monthly MedTech and HealthTech companies, displaying venture capital following recipients: published overview financing trends in the European life science industry ▪ Corporates / Executives ▪ Venture capital investors focusing on the ▪ Institutional investors ▪ Family Offices / High- venture capital ▪ Private equity investors net-worth individuals financing ▪ Advisors environment in the Scope Biotech, Pharmaceutical, The selection of companies is based on the following criteria: Availability MedTech and HealthTech ▪ Focus on transactions with European headquartered life science The FCF Life Sciences Venture Capital Monitor - Europe is available segments, and can companies and available deal volume on FCF’s website at “https://www.fcf.de/de/life-sciences/” be used as a quick ▪ Companies operating in the Biotech, Pharmaceutical, MedTech, reference for HealthTech, Services or other life science related sectors Data investors, corporates and professionals ▪ The Biotech sector is further divided into the following therapy All input data is provided by Pitchbook or GlobalData and is not areas / indications: Cardiovascular, Central Nervous System, independently verified by FCF. Ratio and multiple calculations are Dermatology, Ear Nose Throat Disorders, Gastrointestinal, driven based on the input data available. For additional information Genetic Disorders, Genito Urinary System And Sex Hormones, and disclaimer, please refer to the last page More advanced, Hematological Disorders, Hormonal Disorders, Immunology, detailed and / or Infectious Disease, Male Health, Metabolic Disorders, Mouth and Dental Disorders, Musculoskeletal, Non Malignant Disorders, customized reports Nutritional Disorders, Oncology, Ophthalmology, Respiratory, are available upon Toxicology, Women's Health request To recommend colleagues or fellow investors to be added to the If you have questions, comments or ideas, please do not hesitate mailing list, kindly send an email with the respective contact to contact us information 4 Agenda EUROPEAN VENTURE CAPITAL TRANSACTIONS IN LIFE SCIENCES FEBRUARY 2021 European Venture Capital Transactions in Life Sciences February 2021 Deal Total Vertical - Indication / Volume Raised Overview (YTD) # Date Company HQ Subsector Stage Company Description Series (EURm) (EURm) Deal Synopsis Cumulative Financing Volume (EURm) Provider of a healthcare platform Nerve Stimulation 10,000 intended to use bioelectronic The company raised GBP 991,881 of angel funding on December 31, 2020, putting the 1 28-02-21 NuroKor GBR MedTech Devices / - 1 2 technology to work in natural company's pre-money valuation at GBP 12.97 million. 8,000 On market harmony with the body system. 6,000 4,000 The company raised EUR 1.5 million of venture funding on February 26, 2021. The company will use the funding to conduct a health economic trial and complete the 1,333 Developer of a digital healthcare 2,000 approval process of the Kata app by the German Federal Institute for Drugs and 2021 Respiratory Diseases / assistant application designed to 2020 2 26-02-21 VisionHealth DEU HealthTech C 2 3 Medical Devices, BfArM, as a digital health application within the framework of the On market control respiratory diseases in 0 German Digital Health Care Act (DVG), which will enable permanent reimbursement everyday life. Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec by german health insurance companies, to enter the market in Germany and generate Financing Volume (February 2021): EUR 403m revenue, via licensing Kata to pharmaceutical and medtech companies. Subsectors Indications1 Healthcare Medical Device for Developer of a medical device Services The company raised EUR1.0625 million of equity crowdfunding on February 26, 2021 3 26-02-21 VB Devices ESP MedTech Varicose Veins / designed to treat varicose veins - 1 1 Others putting the pre-money valuation at EUR 5.5 million. HealthTech On market with sclerotherapy. 4% Genetic 13% 10% Disorders 7% Oncology Immunology 38% MedTech EUR EUR 19% 9% 1,333m 889m Developer of a genetic inference 67% 11% Genomic Sequence Data technology designed to lead the The company raised $30 million of venture funding on February 25, 2021. The funds Biotech / Central 4 25-02-21 Genomics GBR HealthTech Analysis / genomic transformation by finding C 25 76 will be used to expand its work building a patient-centric, population health platform Pharma Nervous 22% System On market new drug targets for serious that unlocks a more proactive, precise and personalised form of healthcare. diseases. Metabolic Disorders Top Company Origins Top Investor Origins Developer of DO-2 program The company raised EUR 999,996 of venture funding on February 24, 2021, putting Biotech / Oncology / 5 24-02-21 DeuterOncology BEL intended to provide oncology A 1 1 the company's pre-money valuation at EUR 399,750. The fund will be used to advance Others Pharma Phase II services for clinicians and patients. the development of our lead program DO-2 towards Phase I clinical trials. Others 14% 25% 10% 35% 36% EUR EUR 11% 1,333m 6% 1,333m Developer of diagnostic technology The company raised GBP 800,000 of venture funding on February 24, 2021. The funds 7% Diagnostics / intended to facilitate molecular 6 24-02-21 Linear Diagnostics GBR MedTech D < 1 7 will be used to facilitate the ongoing development of the company's high-speed 12% 18% 14% On market diagnostics tests using a simple 12% platform technology for point-of-care diagnostics. optical system. Top 5 Deals Top 5 Investors Deal Deal # of # Company HQ Volume Series # Investor HQ Volume2 Deals Biotech / Other / Developer of drugs intended for The company raised PLN 4 million of angel funding on February 24, 2021. The funds 7 24-02-21 Bioceltix POL - < 1 2 NewAmsterdam Pharma Discovery veterinary therapy and treatments. will be used to fund research and further development of drug candidates. 1 160 A 1 BlackRock 144 1 Pharma Zukunftsfonds 2 Immunocore 144 C 2 60 1 Heilbronn 3 IO Biotech 127 B 3 OrbiMed 26 1 The company raised GBP 5.25 million of venture funding on February 23, 2021, putting Developer of a biotechnology Biotech / Other / the company's pre-money valuation at GBP 7.01 million. The funds will be used to Redmile 8 23-02-21 Newcells Biotech GBR platform designed to produce C 6 15 4 eCential Robotics 100 C 4 26 1 Pharma On market spearhead its international expansion in the USA, growing its existing commercial Group induced pluripotent stem cells. operations and launching innovative new products. Evox The Invus 5 79 C 5 26 1 Therapeutics Group Source: PitchBook as of 22.03.2021; FCF Equity Research; GlobalData Note: All volumes in EURm; financing rounds without deal values are excluded 6 1Only includes biotechnology and pharmaceutical deals; 2 Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round) European Venture Capital Transactions in Life Sciences February 2021 Deal Total Vertical - Indication / Volume Raised Overview (YTD) # Date Company HQ Subsector Stage Company Description Series (EURm) (EURm) Deal Synopsis Cumulative Financing Volume (EURm) Volatile Anesthetic Developer of a technology system 10,000 SageTech Medical The company raised GBP 3.07 million of venture funding on February 23, 2021, putting 9 23-02-21 GBR MedTech Gases / intended to extract and purify A 4 5 Equipment the company's pre-money valuation